Phase 3 Study Demonstrates Intracranial Response in ALK+ NSCLCByBenjamin Solomon, MBBS, PhDNovember 13th 2020Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.